Trial intelligence / Profile preview

PD-1/PDL-1 Blockade +/- Radiotherapy in Metastatic Genitourinary Malignancies

NCT03115801Phase 2Terminated

Sponsor: Weill Cornell Medicine
Start: Nov 2016
Primary completion: Oct 2020
Modality: Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 2, randomised, open-label trial of nivolumab, atezolizumab and pembrolizumab in renal cell carcinoma (RCC) and urothelial carcinoma (UC) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoints: Best Overall Response Rate at 96 weeks and Difference in Best Overall Response Rate at 96 weeks. Started Nov 2016; status: terminated.

Drugs

nivolumabatezolizumabpembrolizumab

Conditions

renal cell carcinoma (RCC)urothelial carcinoma (UC)

Beyond the preview

Go deeper on NCT03115801.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03115801.